Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
LEVI STRAUSS & CO | Director | Class B Common Stock | 122,275 | $2.69 M | $21.96 | May 23, 2024 | Direct |
LEVI STRAUSS & CO | Director | Class A Common Stock | 51,909 | $1.14 M | $21.96 | May 23, 2024 | Direct |
Revance Therapeutics, Inc. | Director | Common Stock | 43,606 | $166 K | $3.80 | May 1, 2024 | Direct |
Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23,458 | May 1, 2024 | Direct |